Skip to main content
OpenTrials
Completed

NCT Number: NCT02430805

Predisposition and Transition Mechanisms From Arterial Hypertension to Heart Failure

This project aims at investigating the genetic, genomic and proteomic basis of hypertension and susceptibility to hypertension-related end organ damage (renal damage and heart failure). It will include cross sectional as well as follow-up studies with a large number of subjects and variety of phenotypes, to explore the pathophysiology of hypertension and hypertension-related disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre D'Investigation Clinique de Strasbourg, Strasbourg, Alsace, France

Loading trial locations.

About this study

In all index patients and recruited family members, recorded data will include the following :

  • Past medical history, drug history and family history
  • Physical examination
  • Height, weight, waist and hip circumference
  • Cardiac examination
  • Vascular examination
  • Blood pressure
  • Plasma and urine samples
  • Body composition (DEXA)
  • Tissue Doppler imaging

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • index patient :
  • Caucasian patients of either sex who were diagnosed to have essential hypertension (as defined below) before the age of 50 y.
  • The index patient should not be older than 60 years at the time of enrolment.
  • Definition of hypertension for the index patient:
  • If untreated: Systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 95 mmHg.
  • If already on treatment: Treatment with more of 2 different antihypertensive drugs at the time of enrolment.
  • At least three first degree relatives of whom at least one should be affected and at least one be from a different generation (parents or offspring aged 18 years or above) must be willing to participate in the family study. For definition of hypertension in relatives of the index patient see below.
  • Written informed consent
  • family
  • at least three other first degree relatives must be willing to participate in the family study:
  • at least one first-degree relative must be affected with diagnosis of hypertension made before age of 50 years AND
  • at least one first degree relative must be from a different generation (offspring or parents).

Exclusion criteria

  • index patient :
  • Any known form of secondary hypertension, including sleep apnoea syndrome
  • Any known previous clinical complications of hypertension (angina, MI, stroke, TIA, peripheral artery disease) at any time
  • Any known renal disease, including GFR < 60 mL/min as estimated by the abbreviated MDRD formula, or kidney stones
  • Kidney or other organ transplantation
  • Type 1 diabetes mellitus
  • Heart failure stage D (AHA/ACC criteria)
  • Any malignant concomitant diseases or history of malignant diseases within the last five years, with exception of treated squamous skin cancer or basalioma
  • Clinical or laboratory signs of acute infection, especially urinary tract infection
  • Systemic inflammatory diseases, such as autoimmune diseases, connective tissue diseases or collagenoses.
  • Steroids or any other immunosuppressive drug
  • Severe known liver disease (ALT or gamma-GT above three-fold of upper normal limit)
  • Current alcohol consume of more than 21 drinks/week (1 drink = a bottle (0,33 l) beer, a glass (0,2 l) of wine, or 4 cl = 40 ml of spirit (40%)) or drug abuse such as cocaine
  • family
  • any organ transplantation
  • any malignant concomitant disease
  • acute infection
  • systemic inflammatory disease
  • severe liver disease
  • current alcohol or drug abuse

Treatment and study plan

dna extraction and genotyping

Other

blood and urine sample

Primary outcomes

  1. genetic biomarkers

    Time frame: time point 1 : first day ; Time point

Secondary outcomes

  1. oxidative stress markers

    Time frame: time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years

  2. microinflammation markers

    Time frame: time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years

  3. renal function and damage markers

    Time frame: time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years

  4. cardiac and large artery growth, remodelling dysfunction and failure markers

    Time frame: time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Collaborators

  • Network of Excellence 6 PCRD

Registry information

Official study title

Genetics and Genomics of Hypertension Associated With Microinflammation, Oxydative Stress, Chronic Renal Disease and Heart Failure (A2-B2-B3)

Acronym: Hypercare

Important dates

Study start
2008
Primary completion
2015
Study completion
2015
First posted
Apr 30, 2015
Registry last updated
Apr 30, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.